In those entities, e.g. Histone H3-, or IDH-wildtype glioblastomas, where no driver mutations are found, identification of molecular heterogeneity and characterisation of molecular subgroups in histologically similar tumours will help in the design of novel, more effective targeted therapies. The gene discussed is H3C3; the disease is neoplasm.